Device Trial Radar · NCT04862156
WP02 Continued Access Study
Last checked: Nov 20, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
19
Actual
Start
Oct 10, 2021
Primary completion
Jul 31, 2022
Study completion Jul 7, 2023
Sponsor
- Lead sponsor
- OrganOx Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- North American Science Associates Ltd.
- First posted
- Apr 27, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The single-arm continued access phase will be used to collect additional effectiveness and safety data to support the objectives and outcomes of the original IDE pivotal study.
Conditions
- Liver Transplantation
Interventions
Normothermic Machine Perfusion (NMP)Device
Storage and transportation of the donated liver using the OrganOx metra device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Early Allograft Dysfunction (EAD)Time frame: 7 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Colorado
Aurora, Colorado
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.